Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Transgene SA

TNG.PA ✓ COMPLIANT ☆ Track — members

Euronext Paris · Healthcare · Biotechnology & Medical Research ·

France Micro Cap Analyst: BUY

Last Close

$0.83

▲ +0.00%

Market Cap $231.19M · Vol 64.44K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$231.19M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

+46.08%

YoY

RSI (14)

49.12

Momentum

Beta

0.79

vs Market

52W High

$1.74

52.29% below

52W Low

$0.82

2.53% above

Volume

64.44K

Avg 40.98K

P/B

2.16

Price-to-book

ROE

N/A

Return on equity

Free Float

19.13%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Transgene SA (TNG.PA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TNG.PA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.55%

-3.23%

-14.49%

-15.29%

YTD

-25.00%

-30.43%

-55.01%

-68.56%

Financials & Valuation

TTM · Annual

Total Revenue	$8.05M
Net Income	$-44,071,738.00
Revenue Growth (YoY)	-13.29%
Gross Margin	100.00%
Operating Margin	-511.29%
Net Profit Margin	-547.24%
ROE	N/A
ROA · ROIC	-41.46% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	20.23
P/B	2.16
P/FCF	N/A
EPS Growth	+46.08%
Outstanding Shares	278.56M

Technical Indicators

50-Day SMA	$0.85
200-Day SMA	$1.00
RSI (14)	49.12
Beta	0.79
52-Week High	$1.74
52-Week Low	$0.82

Volume Today	64.44K
Avg Daily Volume (30D)	40.98K
Relative Volume	1.57x
Volatility (10D)	13.65
Volatility (30D)	16.39
Free Float	19.13%

Analyst Consensus

BUY

Current Price $0.83

Mean Target $1.70

52W Low$0.82 52W High$1.74

Current

Target

$0.82 $1.74

Current Analyst target

+103.51% upside potential · 2 analysts

Identifiers

ExchangeEuronext Paris

FIGIBBG001S99KH5

ISINFR0005175080

CountryFrance

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 24, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).